Roche's Fenebrutinib Results Come as a Positive Surprise -- Market Talk

Dow Jones11-10

1052 GMT - Roche's fenebrutinib results came as a positive surprise, Vontobel analyst Stefan Schneider writes in a note. The Swiss pharmaceutical group said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, showing reduced relapse rates and delayed disability progression in different disease forms. Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says. The analyst notes that fenebrutinib could support Roche's neuroscience revenue once Ocrevus patents begin to expire in 2029. Shares are up 1.8% at 273.20 Swiss Francs.(najat.kantouar@wsj.com)

(END) Dow Jones Newswires

November 10, 2025 05:53 ET (10:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582827509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582827509","market":"other","top_or_hot":-1,"title":"Roche's Fenebrutinib Results Come as a Positive Surprise -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1052 GMT - Roche's fenebrutinib results came as a positive surprise, Vontobel analyst Stefan Schneider writes in a note. The Swiss pharmaceutical group said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, showing reduced relapse rates and delayed disability progression in different disease forms. Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says. The analyst notes that fenebrutinib could support Roche's neuroscience revenue once Ocrevus patents begin to expire in 2029. Shares are up 1.8% at 273.20 Swiss Francs.(najat.kantouar@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 05:53 ET (10:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Fenebrutinib Results Come as a Positive Surprise -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Fenebrutinib Results Come as a Positive Surprise -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-10 18:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1052 GMT - Roche's fenebrutinib results came as a positive surprise, Vontobel analyst Stefan Schneider writes in a note. The Swiss pharmaceutical group said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, showing reduced relapse rates and delayed disability progression in different disease forms. Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says. The analyst notes that fenebrutinib could support Roche's neuroscience revenue once Ocrevus patents begin to expire in 2029. Shares are up 1.8% at 273.20 Swiss Francs.(najat.kantouar@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 05:53 ET (10:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582827509","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582827509","pubTimestamp":1762771980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1052 GMT - Roche's fenebrutinib results came as a positive surprise, Vontobel analyst Stefan Schneider writes in a note. The Swiss pharmaceutical group said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, showing reduced relapse rates and delayed disability progression in different disease forms. Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says. The analyst notes that fenebrutinib could support Roche's neuroscience revenue once Ocrevus patents begin to expire in 2029. Shares are up 1.8% at 273.20 Swiss Francs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03165":"华夏欧优股对冲","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"罗氏的Fenebrutinib业绩令人惊喜——Market Talk","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"1052 GMT - Roche's fenebrutinib results came as a positive surprise, Vontobel analyst Stefan Schneider writes in a note. The Swiss pharmaceutical group said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, showing reduced relapse rates and delayed disability progression in different disease forms. Given adverse events seen with other trials, expectations for fenebrutinib in relapsing multiple sclerosis were modest, he says. The analyst notes that fenebrutinib could support Roche's neuroscience revenue once Ocrevus patents begin to expire in 2029. Shares are up 1.8% at 273.20 Swiss Francs.(najat.kantouar@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 05:53 ET (10:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582827509","isCrawlerRequest":true}